Evidence map›Paper›PMID 34980596›Full record

Trial reportEuropean journal of hospital pharmacy : science and practice2023

Impact of hospital pharmacist-delivered individualised pharmaceutical service intervention on clinical and patient-reported outcomes in patients with hypertension: a randomised controlled trial.

Nabina Paudel, Shakti Shrestha, Nirmal Raj Marasine, Pitambar Khanal, Sushant Aryal, Daniel Erku, Arjun Poudel

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of hospital pharmacy : science and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Nabina PaudelSchool of Pharmacy, Kathmandu University, Dhulikhel, Nepal.
Shakti ShresthaSchool of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia shakti.shrestha@uq.edu.au.ORCID 0000-0003-0344-091X
Nirmal Raj MarasineDepartment of Pharmacy, Karnali College of Health Sciences, Kathmandu, Nepal.
Pitambar KhanalDepartment of Pharmacy, Nepalgunj Medical College, Nepalgunj, Nepal.
Sushant AryalSchool of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand.ORCID 0000-0001-6330-8203
Daniel ErkuCentre for Applied Health Economics, Griffith University, Nathan, Queensland, Australia.
Arjun PoudelQuality Use of Medicine Research Network Nepal, Chitwan, Nepal.
Griffith University · AUKarnali Academy of Health Sciences · NPKathmandu University · NPNepal Medical College Teaching Hospital · NPQueensland University of Technology · AUThe University of Queensland · AUUniversity of Canterbury · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with hypertension in Nepal are often known to have poor medication adherence and quality of life. This randomised controlled trial aimed to evaluate the impact of a hospital pharmacist-delivered individualised pharmaceutical service (P-DIPS) intervention on blood pressure, medication adherence and health-related quality of life (HRQoL) among patients with hypertension in a hospital setting in Nepal.

methodsIn an open trial, 56 adult patients with hypertension who had been receiving antihypertensive medication for ≥6 months were randomly allocated to a control group (n=28) which received the usual care and an intervention group (n=28) which received a P-DIPS along with the usual care. The difference in blood pressure, medication adherence and HRQoL between the two groups at baseline, 2 and 4 months was compared using the Mann-Whitney U test, independent t-test or χ

resultsParticipants were mostly ≥40 years (86%) and female (57%). There were no significant differences in the baseline characteristics between the control (C) and intervention (I) groups. At 2 months, the two groups had a significant improvement in the median (IQR) Morisky-Green-Levine (MGL) Medication Adherence Score (I=1 (2) vs C=2 (2); p<0.001) and the median (IQR) mental component of HRQoL (I=43.6 (9.5) vs C=37.5 (8.6); p=0.013). At 4 months, there were significant differences in the median (IQR) values of all the outcome measures between the groups (systolic blood pressure: I=125 (10) mmHg vs C=130 (15) mmHg, p=0.008; diastolic blood pressure: 80 (14) mmHg vs 90 (10) mmHg, p=0.012; MGL score: I=1 (1) vs C=2 (1), p<0.001; physical component of HRQoL: 45.0 (9.0) vs 40.3 (8.2), p=0.046; and mental component of HRQoL: 47.1 (11.1) vs 38.8 (8.5), p=0.003).

conclusionsThe findings suggest that a P-DIPS intervention in the hospital setting of Nepal has a significant potential to improve blood pressure, medication adherence and HRQoL in patients with hypertension.

Indexed as

HypertensionPharmacy Service, HospitalAdultFemaleHospitalsHumansPatient Reported Outcome MeasuresPharmacistsQuality of LifeSalicylates3,5-diisopropylsalicylic acidSalicylatescommunicable diseaseshealth services administrationhospitalhypertensionpharmacy serviceprimary health carerandomized controlled trial

Identifiers

PMID34980596
PMCPMC10647875
OpenAlexW4206133259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.